These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 1638466)

  • 21. Results of a fludarabine induction and alpha-interferon maintenance protocol in pretreated patients with chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma.
    Zinzani PL; Bendandi M; Magagnoli M; Rondelli D; de Vivo A; Benni M; Zamagni E; Cavo M; Tura S
    Eur J Haematol; 1997 Aug; 59(2):82-8. PubMed ID: 9293855
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Idarubicin in low-grade non-Hodgkin's lymphomas.
    Zinzani PL
    Haematologica; 1997; 82(5 Suppl):23-4. PubMed ID: 9402750
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of interferon-alpha in the management of myelomatosis.
    Avvisati G; Mandelli F
    Hematol Oncol Clin North Am; 1992 Apr; 6(2):395-405. PubMed ID: 1582981
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fludarabine in the management of malignant lymphomas.
    Hiddemann W; Pott-Hoeck C
    Drugs; 1994; 47 Suppl 6():50-6. PubMed ID: 7525189
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of interferon-alfa in NHL: still controversial?
    Haase-Statz S; Smalley RV
    Oncology (Williston Park); 1999 Aug; 13(8):1147-59; discussion 1159-60, 1163. PubMed ID: 10499247
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel.
    Cheson BD; Wendtner CM; Pieper A; Dreyling M; Friedberg J; Hoelzer D; Moreau P; Gribben J; Knop S; Montillo M; Rummel M
    Clin Lymphoma Myeloma Leuk; 2010 Feb; 10(1):21-7. PubMed ID: 20223726
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Purine analogs in lymphoproliferative disorders.
    Cheson BD
    Leuk Lymphoma; 1993; 11 Suppl 2():153-9. PubMed ID: 7907252
    [No Abstract]   [Full Text] [Related]  

  • 29. Modulation of chemosensitivity by alpha interferon in multiple myeloma and non-Hodgkin's lymphoma.
    Iaffaioli RV; Facchini G; Tortoriello A; Scala S; Pacelli R; La Mura G; Pagliarulo C; Palmieri G; Caponigro F
    J Exp Ther Oncol; 1996 Jul; 1(4):226-30. PubMed ID: 9414408
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-lasting complete remission of hepatitis C virus (HCV) infection and HCV-associated immunocytoma with alpha-interferon treatment.
    Patriarca F; Silvestri F; Fanin R; Zaja F; Sperotto A; Baccarani M
    Br J Haematol; 2001 Feb; 112(2):370-2. PubMed ID: 11167831
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fludarabine: an active agent in the treatment of previously-treated and untreated low-grade non-Hodgkin's lymphoma.
    Zinzani PL; Lauria F; Rondelli D; Benfenati D; Raspadori D; Bocchia M; Bendandi M; Gozzetti A; Zaja F; Fanin R
    Ann Oncol; 1993 Aug; 4(7):575-8. PubMed ID: 8363989
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of low grade non-Hodgkin's lymphomas with fludarabine.
    Whelan JS; Ganjoo R; Johnson PW; Rohatiner AZ; Lister TA
    Leuk Lymphoma; 1993; 10 Suppl():35-7. PubMed ID: 8481668
    [No Abstract]   [Full Text] [Related]  

  • 33. Fludarabine: a phase II trial in patients with previously treated low-grade lymphoma.
    Falkson CI
    Am J Clin Oncol; 1996 Jun; 19(3):268-70. PubMed ID: 8638539
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current trends in chemotherapy of leukaemias lymphomas and multiple myeloma.
    Kasili EG
    East Afr Med J; 1976 Sep; 53(9):554-9. PubMed ID: 1009883
    [No Abstract]   [Full Text] [Related]  

  • 35. Alpha interferon treatment of low-grade B-cell non-Hodgkin's lymphomas, cutaneous T-cell lymphomas, and chronic lymphocytic leukemia.
    Foon KA; Roth MS; Bunn PA
    Semin Oncol; 1986 Sep; 13(3 Suppl 2):35-42. PubMed ID: 3532334
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interferon-alpha in the treatment of multiple myeloma.
    Khoo TL; Vangsted AJ; Joshua D; Gibson J
    Curr Drug Targets; 2011 Mar; 12(3):437-46. PubMed ID: 21143148
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Report from the 34th annual meeting of the American Society of Hematology, December 4-8, 1992.
    Markman M
    J Cancer Res Clin Oncol; 1993; 119(11):695-6. PubMed ID: 8349726
    [No Abstract]   [Full Text] [Related]  

  • 38. [Role of interferon for the treatment of myeloma].
    Tomita S; Okamoto S
    Nihon Rinsho; 2007 Dec; 65(12):2285-90. PubMed ID: 18069274
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [IFN-alpha consolidation after intensive chemotherapy does not bring any survival advantage in low-grade non-Hodgkin lymphoma].
    Klee M; Illiger HJ
    Strahlenther Onkol; 2001 Sep; 177(9):494-5. PubMed ID: 11591024
    [No Abstract]   [Full Text] [Related]  

  • 40. Galiximab (anti-CD80)-induced growth inhibition and prolongation of survival in vivo of B-NHL tumor xenografts and potentiation by the combination with fludarabine.
    Hariharan K; Chu P; Murphy T; Clanton D; Berquist L; Molina A; Ho SN; Vega MI; Bonavida B
    Int J Oncol; 2013 Aug; 43(2):670-6. PubMed ID: 23764770
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.